Literature DB >> 24030080

Cardiac dysfunction related to cirrhosis.

Odilson Marcos Silvestre, Alberto Queiroz Farias, Fernando Bacal.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 24030080      PMCID: PMC3998145          DOI: 10.5935/abc.20130155

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


× No keyword cloud information.
Dear Editor, A systematic review of Mota and Markman Filho[1] demonstrates that Doppler echocardiography is indicated in cases of cirrhosis, for investigation of pulmonary and vascular complications of cirrhotic cardiomyopathy. We agree that this test may show cardiac abnormalities related to cirrhosis. In our experience, 184 patients prospectively evaluated showed structural cardiac abnormalities at rest, which correlated with the severity of cirrhosis[2]. However, the presence of these abnormalities is not sufficient to characterize cirrhotic cardiomyopathy. The criteria for diagnosis are not yet established or validated internationally. Clinical manifestations occur in conditions of stress. At rest, the heart is functionally normal. Hence, Doppler echocardiography at rest is often insufficient to characterize cirrhotic cardiomyopathy. We are thankful to the statements of Silvestre et al[1], with which we agree and have mentioned in the introduction to our manuscript. Recent reviews[2,3] that address this issue describe a number of abnormalities on Doppler echocardiography at rest, characterizing cirrhotic cardiomyopathy: E/A ratio < 1; E wave deceleration time > 200 ms, isovolumic relaxation time > 80ms, increased left atrial volume, decreased left ventricular contractility, presence of wall hypokinesia and/or akinesia, increased myocardial mass, lowered ejection fraction (< 55%), among others. Sincerely,
  4 in total

Review 1.  Echocardiography in chronic liver disease: systematic review.

Authors:  Vitor Gomes Mota; Brivaldo Markman Filho
Journal:  Arq Bras Cardiol       Date:  2013-03-22       Impact factor: 2.000

Review 2.  Cirrhotic cardiomyopathy.

Authors:  Enrico M Zardi; Antonio Abbate; Domenico Maria Zardi; Aldo Dobrina; Domenico Margiotta; Benjamin W Van Tassell; Benjamin W Van Tassel; Antonella Afeltra; Arun J Sanyal
Journal:  J Am Coll Cardiol       Date:  2010-08-10       Impact factor: 24.094

3.  Impact of the severity of end-stage liver disease in cardiac structure and function.

Authors:  Odilson Marcos Silvestre; Fernando Bacal; Danusa de Souza Ramos; Jose L Andrade; Meive Furtado; Vincenzo Pugliese; Elisangela Belleti; Wellington Andraus; Flair José Carrilho; Luiz Augusto Carneiro D'Albuquerque; Alberto Queiroz Farias
Journal:  Ann Hepatol       Date:  2013 Jan-Feb       Impact factor: 2.400

Review 4.  Cirrhotic cardiomyopathy.

Authors:  Søren Møller; Jens H Henriksen
Journal:  J Hepatol       Date:  2010-03-31       Impact factor: 25.083

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.